Considering this potentially paradoxical impact, we aimed to determine whether MASLD was more prevalent in acromegaly patients, assess the risk of hepatic fibrosis, and clarify the uncertain relationship between MASLD and GH/IGF-1 levels. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.